Horizon 137 Male Natera, Inc.
United States | 130 | 133 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
|
Horizon 274 Male Natera, Inc.
United States | 244 | 254 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
|
Usher Syndrome (NGS Panel and Copy Number Analysis) MNG Laboratories (Medical Neurogenetics, LLC.)
United States | 10 | 12 | - C Sequence analysis of the entire coding region
|
CLRN1 Prenatal Sequence Analysis (GeneAware) (Prenatal Sequence Analysis) Baylor Genetics
United States | 1 | 1 | - E Sequence analysis of select exons
|
Super Panel Plus NxGen MDx
United States | 116 | 117 | - D Deletion/duplication analysis
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Universal Panel Plus NxGen MDx
United States | 21 | 22 | - D Deletion/duplication analysis
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Ashkenazi Jewish Panel NxGen MDx
United States | 20 | 21 | - D Deletion/duplication analysis
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
|
Super Panel 113 NxGen MDx
United States | 113 | 115 | - D Deletion/duplication analysis
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 106 plus TSE Natera, Inc.
United States | 103 | 107 | - E Enzyme assay
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 106 Natera, Inc.
United States | 103 | 106 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 274 Plus TSE Natera, Inc.
United States | 265 | 275 | - E Enzyme assay
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 274 Natera, Inc.
United States | 265 | 274 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 137 plus TSE Natera, Inc.
United States | 135 | 138 | - E Enzyme assay
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 137 Natera, Inc.
United States | 135 | 137 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 274 Natera, Inc.
United States | 265 | 274 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Hearing Loss Test GeneDx
United States | 56 | 150 | - D Deletion/duplication analysis
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
|
Ciliopathies Asper Biogene Asper Biogene LLC
Estonia | 166 | 120 | - C Sequence analysis of the entire coding region
|
Hearing Loss, Comprehensive Panel CNH Molecular Diagnostics Laboratory Childrens National Hospital
United States | 142 | 84 | - C Sequence analysis of the entire coding region
|
Ashkenazi Jewish Diseases Asper Biogene Asper Biogene LLC
Estonia | 43 | 37 | - C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Foresight Myriad Genetics, Inc.
United States | 112 | 110 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
